Aptiv Solutions Launches ADDPLAN DF 3.0
ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0
ICON announced that Aptiv Solutions, an ICON company for the design and implementation of adaptive trials, has released ADDPLAN DF 3.0, which incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials. Accurate estimation of MTD can minimize safety and efficacy issues leading to late phase clinical trial failures.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
